Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.

Date publication

mai 2024

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz S, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38729566

Résumé

In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC) with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3.

Mots clés

CDK4/6 inhibitor, HR-positive/HER2-negative, abemaciclib, advanced breast cancer, first-line therapy, overall survival

Référence

Ann Oncol. 2024 05 8;: